Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIGIN2: gemcitabine + ivonescimab in advanced NSCLC resistant to prior immunotherapy
2026-526043-36-00Phase 2Authorised
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2026
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of ivonescimab and gemcitabine in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Objective response rate. Planned start Oct 2026; status: authorised.
02
Drugs
ivonescimabgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2026-526043-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526043-36-00.